

# Seung Tae Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1117759/publications.pdf>

Version: 2024-02-01

237  
papers

7,589  
citations

109321

35  
h-index

66911

78  
g-index

240  
all docs

240  
docs citations

240  
times ranked

11554  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	30.7	1,592
2	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	30.7	1,071
3	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	1.6	370
4	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	183
5	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	9.4	155
6	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152
7	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
8	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137
9	Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1993-1999.	4.1	126
10	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	9.4	105
11	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. <i>Lung Cancer</i> , 2012, 75, 82-88.	2.0	94
12	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	1.8	85
13	Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014, 50, 2822-2830.	2.8	79
14	Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 659-667.	2.3	73
15	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	2.3	71
16	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. <i>Modern Pathology</i> , 2016, 29, 1095-1103.	5.5	70
17	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	1.8	68
18	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020, 216, 152881.	2.3	67

#	ARTICLE	IF	CITATIONS
19	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
20	Efficacy of Mobile Health Care Application and Wearable Device in Improvement of Physical Performance in Colorectal Cancer Patients Undergoing Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2018, 17, e353-e362.	2.3	62
21	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	2.8	62
22	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017, 8, 13320-13328.	1.8	60
23	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	1.8	57
24	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 15365.	3.3	54
25	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	7.0	54
26	Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1976-1988.	7.7	53
27	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4001-4001.	1.6	53
28	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	1.8	53
29	Early Tumor Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	9.4	52
30	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	1.8	48
31	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016, 7, 43492-43503.	1.8	45
32	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. <i>Scientific Reports</i> , 2015, 5, 9289.	3.3	43
33	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. <i>Oncotarget</i> , 2017, 8, 15014-15022.	1.8	42
34	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 170-175.	1.0	39
35	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. <i>Oncotarget</i> , 2016, 7, 4024-4035.	1.8	36
36	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016, 16, 120.	2.6	35

#	ARTICLE	IF	CITATIONS
37	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. <i>Cancer</i> , 2010, 116, 3025-3033.	4.1	34
38	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	4.1	34
39	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	2.5	34
40	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	5.3	34
41	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. <i>PLoS ONE</i> , 2014, 9, e111693.	2.5	34
42	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Oncolmmunology</i> , 2017, 6, e1356150.	4.6	32
43	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	1.8	32
44	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 171-177.	0.6	31
45	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	31
46	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. , 2022, 10, e005041.		31
47	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 979-985.	2.3	30
48	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 13.	2.3	28
49	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987112.	3.2	27
50	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	1.9	26
51	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	1.0	26
52	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. <i>Nature Communications</i> , 2021, 12, 975.	12.8	26
53	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	1.8	25
54	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	2.6	25

#	ARTICLE	IF	CITATIONS
55	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 447-56.	1.4	25
56	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. <i>Cancer Genomics and Proteomics</i> , 2014, 11, 259-66.	2.0	25
57	The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. <i>Medical Oncology</i> , 2010, 27, 1277-1285.	2.5	24
58	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014, 4, 7592.	3.3	24
59	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017, 17, 211.	2.6	24
60	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. <i>Oncologist</i> , 2017, 22, 1354-1361.	3.7	24
61	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	1.8	24
62	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2- Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017, 10, 469-475.	3.7	23
63	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.	1.8	23
64	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	1.8	23
65	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. <i>Translational Oncology</i> , 2016, 9, 173-178.	3.7	22
66	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. <i>Journal of Cancer</i> , 2018, 9, 3032-3037.	2.5	22
67	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 152434.	2.3	22
68	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	1.8	21
69	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	3.7	21
70	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020, 216, 152878.	2.3	21
71	The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. <i>Medical Oncology</i> , 2010, 27, 1149-1154.	2.5	20
72	Disappearing or residual tiny (<math>\leq 5\text{mm}</math>) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. <i>European Radiology</i> , 2017, 27, 3088-3096.	4.5	20

#	ARTICLE	IF	CITATIONS
73	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017, 8, 1395-1399.	2.5	20
74	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	2.8	20
75	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	8.2	20
76	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	3.2	20
77	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	1.8	20
78	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	3.0	19
79	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017, 8, 2809-2815.	2.5	18
80	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	2.6	17
81	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016, 7, 1044-1048.	2.5	17
82	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	2.3	17
83	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	2.1	17
84	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000670.	4.5	17
85	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	8.2	17
86	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015, 8, 40-46.	3.7	16
87	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016, 1, e000009.	4.5	16
88	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , 2017, 8, 2713-2719.	2.5	16
89	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	3.7	16
90	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 243-250.	2.8	16

#	ARTICLE	IF	CITATIONS
91	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i> -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 222-232.	3.0	16
92	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	1.8	16
93	Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer: A double-blind randomized phase 3 study. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4066.	1.6	16
94	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 27-31.	1.0	15
95	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015, 6, 40026-40035.	1.8	15
96	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	1.8	15
97	Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. <i>Oncology</i> , 2010, 79, 78-84.	1.9	14
98	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017, 22, 1169-1177.	3.7	14
99	The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution. <i>Medicine (United States)</i> , 2016, 95, e3534.	1.0	13
100	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 375-383.	3.8	13
101	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 701668.	4.8	13
102	Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis. <i>Annals of Coloproctology</i> , 2021, 37, 244-252.	2.0	13
103	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	2.5	12
104	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.6	12
105	Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199). <i>Journal of Clinical Oncology</i> , 2020, 38, 3503-3503.	1.6	12
106	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016, 7, 19610-19619.	1.8	12
107	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 1128-1134.	3.0	12
108	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152947.	2.3	11
110	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	3.0	11
111	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	1.9	11
112	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	2.6	10
113	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 790-795.	3.0	10
114	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016, 9, 197-202.	3.7	10
115	MET is overexpressed in microsatellite instability-high gastric carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 433-438.	2.3	10
116	A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. <i>Oncologist</i> , 2020, 25, e186-e193.	3.7	10
117	Reducing tumor invasiveness by ramucirumab and TGF $\alpha$ receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. <i>Cancer Medicine</i> , 2021, 10, 7253-7262.	2.8	10
118	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	3.2	10
119	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 34-44.	1.5	10
120	Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?. <i>Cancer Research and Treatment</i> , 2014, 46, 48-54.	3.0	10
121	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	2.6	9
122	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 3172-3178.	2.5	9
123	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 612-622.	2.8	9
124	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 152, 19-25.	0.6	9
125	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	3.2	9
126	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 107492-107499.	1.8	9



#	ARTICLE	IF	CITATIONS
127	The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 457-62.	1.4	9
128	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	3.0	9
129	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	3.7	8
130	The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3307.	2.0	8
131	3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor. <i>Oncotarget</i> , 2017, 8, 36484-36491.	1.8	8
132	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	3.7	8
133	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	3.7	8
134	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. <i>Scientific Reports</i> , 2019, 9, 19439.	3.3	8
135	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	8
136	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2021, 13, 59.	3.7	8
137	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	3.0	8
138	SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. <i>Scientific Reports</i> , 2018, 8, 16892.	3.3	7
139	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1791-1796.	2.5	7
140	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	2.5	7
141	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019, 10, 6185-6190.	2.5	7
142	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. <i>Frontiers in Oncology</i> , 2020, 10, 225.	2.8	7
143	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	7
144	Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. <i>Oncology and Therapy</i> , 2021, 9, 557-573.	2.6	7

#	ARTICLE	IF	CITATIONS
145	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	7
146	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.	1.4	6
147	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	2.5	6
148	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (â‰¥45 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 5811-5820.	1.1	6
149	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. <i>Translational Oncology</i> , 2019, 12, 1488-1495.	3.7	6
150	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 501-508.	2.3	6
151	Correlation between RICTOR overexpression and amplification in advanced solid tumors. <i>Pathology Research and Practice</i> , 2020, 216, 152734.	2.3	6
152	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	2.3	6
153	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	1.9	6
154	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. <i>European Radiology</i> , 2022, 32, 1-11.	4.5	6
155	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686.	1.8	6
156	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. <i>Radiation Oncology Journal</i> , 2015, 33, 83.	1.5	6
157	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 834104.	2.8	6
158	Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	1.6	6
159	The Efficacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1031-1036.	1.3	5
160	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018, 9, 3394-3399.	2.5	5
161	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	2.5	5
162	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019, 9, 1327.	2.8	5

#	ARTICLE	IF	CITATIONS
163	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	3.6	5
164	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020, 12, 943.	3.7	5
165	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	2.5	5
166	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017, 8, 73974-73980.	1.8	5
167	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	2.0	4
168	CDH1 mutations in gastric cancers are not associated with family history. <i>Pathology Research and Practice</i> , 2020, 216, 152941.	2.3	4
169	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	2.5	4
170	Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9514-9514.	1.6	4
171	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2570-2570.	1.6	4
172	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 355-355.	1.6	4
173	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4508-4515.	0.0	4
174	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). <i>Translational Cancer Research</i> , 2020, 9, 3222-3230.	1.0	3
175	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020, 15, 203-209.	3.6	3
176	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEX-T-2 trial—A feasibility analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11534-11534.	1.6	3
177	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatred gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4061-4061.	1.6	3
178	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	1.6	3
179	Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 47-47.	1.6	3
180	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3023-3023.	1.6	3

#	ARTICLE	IF	CITATIONS
181	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 792340.	2.8	3
182	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. <i>PLoS ONE</i> , 2019, 14, e0215080.	2.5	2
183	Analysis of inpatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1047.	0.9	2
184	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	1.6	2
185	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4049-4049.	1.6	2
186	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial. <i>Journal of Cancer</i> , 2022, 13, 1097-1102.	2.5	2
187	Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/ <i>nab</i> -paclitaxel.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS632-TPS632.	1.6	2
188	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 2173-2178.	2.5	1
189	Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer. <i>Tumori</i> , 2017, 103, 345-352.	1.1	1
190	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	1
191	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020, 15, 67-73.	3.6	1
192	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	2.6	1
193	Abstract CT234: VASTUS - a phase 1b/2a basket trial of a new PARP inhibitor, IDX-1197, including PARP inhibitor resistant cohort. , 2021, , .		1
194	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. <i>In Vivo</i> , 2021, 35, 499-505.	1.3	1
195	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid) Tj ETQq1 1 0.784314 rgBT /Overl... e12540-e12540.	1.6	1
196	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15610-e15610.	1.6	1
197	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14501-e14501.	1.6	1
198	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10586-10586.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	1.6	1
200	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. Journal of Clinical Oncology, 2017, 35, 4024-4024.	1.6	1
201	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. Journal of Clinical Oncology, 2019, 37, 344-344.	1.6	1
202	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	1
203	Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.. Journal of Clinical Oncology, 2022, 40, e16102-e16102.	1.6	1
204	Comprehensive landscape of tumor angiogenesis via integrating RNA sequencing and three-dimensional microphysiological system.. Journal of Clinical Oncology, 2022, 40, e16058-e16058.	1.6	1
205	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/ nab -paclitaxel.. Journal of Clinical Oncology, 2022, 40, e16299-e16299.	1.6	1
206	Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 432-438.	1.3	0
207	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. Journal of Cancer, 2021, 12, 5681-5686.	2.5	0
208	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.. Journal of Clinical Oncology, 2014, 32, 3608-3608.	1.6	0
209	Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib: A Korean multicenter study.. Journal of Clinical Oncology, 2015, 33, 462-462.	1.6	0
210	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN).. Journal of Clinical Oncology, 2015, 33, e22173-e22173.	1.6	0
211	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	1.6	0
212	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).. Journal of Clinical Oncology, 2016, 34, 65-65.	1.6	0
213	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. Journal of Clinical Oncology, 2016, 34, e15628-e15628.	1.6	0
214	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. Journal of Clinical Oncology, 2016, 34, 4091-4091.	1.6	0
215	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. Journal of Clinical Oncology, 2016, 34, e15153-e15153.	1.6	0
216	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. Journal of Clinical Oncology, 2017, 35, 589-589.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	1.6	0
218	Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity.. Journal of Clinical Oncology, 2017, 35, e23068-e23068.	1.6	0
219	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. Journal of Clinical Oncology, 2017, 35, e15686-e15686.	1.6	0
220	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0
221	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
222	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. Journal of Clinical Oncology, 2019, 37, 213-213.	1.6	0
223	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.. Journal of Clinical Oncology, 2019, 37, 4064-4064.	1.6	0
224	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research, 2019, 8, 2107-2112.	1.0	0
225	Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.. Journal of Clinical Oncology, 2020, 38, e22011-e22011.	1.6	0
226	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. Journal of Clinical Oncology, 2020, 38, e16541-e16541.	1.6	0
227	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	1.6	0
228	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	1.6	0
229	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
230	Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience.. Journal of Clinical Oncology, 2022, 40, e16099-e16099.	1.6	0
231	Solid tumor patients with G12V and G13D <i>KRAS</i> aberrations have poor survival following ICI treatment.. Journal of Clinical Oncology, 2022, 40, e14567-e14567.	1.6	0
232	Landscape of tumor mutation burden and correlation to clinical outcomes in 1,744 solid cancers.. Journal of Clinical Oncology, 2022, 40, 2667-2667.	1.6	0
233	Exosome in ascites can be a potential therapeutic target for gastric cancer with malignant ascites.. Journal of Clinical Oncology, 2022, 40, e15008-e15008.	1.6	0
234	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0

#	ARTICLE	IF	CITATIONS
235	ARTISTRY-6: Nivolumab monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9609-TPS9609.	1.6	0
236	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4045-4045.	1.6	0
237	Tumor microenvironment (TME) dynamics following capecitabine/oxaliplatin (CapeOx) plus pembrolizumab in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4053-4053.	1.6	0